about
Imputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesIn Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell typeTargeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma CellsGenome-wide association study identifies two susceptibility loci for osteosarcomaMolecular profiling of chordoma.The fine-tuning of TRAF2-GSTP1-1 interaction: effect of ligand binding and in situ detection of the complexNucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.Modulation of the osteosarcoma expression phenotype by microRNAsCD99 acts as an oncosuppressor in osteosarcomaChemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy.An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.The role of basic research in clinical treatment of Ewing's sarcoma and osteosarcoma.Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors.The expression of ccn3(nov) gene in musculoskeletal tumorsThe metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kitA Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with OsteosarcomaCombined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors.Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma.Caveolins in the development and diseases of musculoskeletal system.Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.Emerging drugs for high-grade osteosarcoma.Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP).Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.Advances in emerging drugs for osteosarcoma.Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.An update on chemotherapy for osteosarcoma.Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance.Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.The pharmacogenomics of osteosarcoma.Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcomaTargeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines.miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents.
P50
Q23924183-5B0B10F0-8389-4627-AD8D-45FE825471A4Q24170413-B7C2F7D3-72C0-4C60-92B1-D9612024EEF2Q28244685-68D04FE7-80D6-4DD8-91C6-7A0B28E644BAQ28554501-0DBD539F-F8D4-4330-A178-8F1A0C502782Q28659642-A13EA52A-F2A1-4D84-956B-6B153C1D3DEEQ33275130-280C725D-0770-416F-B2DC-E90F9FFD0BDAQ33695114-3D04B292-F340-483B-80E4-DECB9FD88FECQ33985880-0DCA6347-2FA9-4E24-979B-4B7858F81DDDQ34469322-A7625928-189E-44A0-BA2F-8DDC2F36889DQ34483649-7844B97C-15CC-4D2E-804A-35A2705F2937Q34700290-D017DC18-645F-47F3-B09F-336556D0F47AQ35085839-A0710660-CE4F-4070-8AF0-2B83BB023A16Q35103838-071D601B-2F31-4A33-A943-3EFBE6E2CC03Q35634897-92A4D73F-1147-43D9-BB44-CCDB8C2FBF36Q35782214-F0CB972D-9137-4595-BD2B-B018760F1F56Q35788810-1E0928A1-8D13-44F7-8190-0FC738C47181Q35829711-5EECA545-2718-4424-98E6-091D165774E7Q36029709-356AE019-0B5D-43EA-AD09-1458A34BA7B6Q37078506-E244A98E-6867-4298-96E6-9B50419753D8Q37323073-E3AC6069-7B60-44D5-8250-57B671397F1EQ37432918-5010D514-8F61-4097-9434-5AA53872B501Q37641721-03E15873-9423-4BE4-97B9-0C5D0BDC564FQ37778400-341721AC-F301-43FF-89B6-91D889BE6056Q38352962-BBFF0E71-9A83-4F0A-8409-13D30477EF1BQ38478426-1FB87999-1F8A-47A0-9A2C-65714A258C18Q38506118-ABB24B76-9F42-4A89-B66B-A94F57469D29Q38533459-2D05F3A7-E5E5-46E2-91C5-E6E173712BC2Q38619114-52318F0C-CBC3-4C03-B316-FA588B5F3911Q38734066-51AC87F1-E881-48D3-ABA5-1030D2104C16Q38759270-005464F0-D318-485E-A553-4B0C6D58B6E7Q38775062-21E54DAF-C76C-440D-A87B-57A3948469B5Q38791215-5D424167-CDA3-41B1-9CC4-9895A8C5482EQ38809116-1483FB7C-C8FB-4676-8BE9-DA558F4022EAQ38848413-53A0A82D-F41E-41D4-B51B-B6C7BCB8D817Q38959358-1B581B38-93A8-4BC0-B550-41EFA3FD95BDQ39246205-C39C82AD-89B3-4040-90CA-E385FEF864BFQ39446187-96BC64BD-FC67-4246-8F53-DB263FBF62E8Q39465507-5DC4BB09-A5F5-4E76-888E-FFADB4401F46Q39553187-25206BD0-F206-4E3E-ADC3-BFD23A0EAF18Q39581986-2EA770AC-21D4-4F6A-990B-7120D3D0692A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Massimo Serra
@ast
Massimo Serra
@en
Massimo Serra
@es
Massimo Serra
@sl
type
label
Massimo Serra
@ast
Massimo Serra
@en
Massimo Serra
@es
Massimo Serra
@sl
prefLabel
Massimo Serra
@ast
Massimo Serra
@en
Massimo Serra
@es
Massimo Serra
@sl
P1053
J-4878-2016
P106
P1153
7203064339
P21
P31
P3829
P496
0000-0003-0742-1177